OBJECTIVE: For several chronic inflammatory disease states, therapy is enhanced by improving the pharmacokinetic properties of anti-inflammatory drugs through conjugation with polyethylene glycol. We hypothesized that part of the beneficial action of PEGylated drugs may be derived from the anti-inflammatory properties of polyethylene glycol (PEG) itself. DESIGN: Randomized, double-blinded, controlled ex vivo and in vivo laboratory studies. SETTING: University research laboratories. SUBJECTS: Human neutrophils and mononuclear cells, macrophage cell line, and adult rats and mice. INTERVENTIONS: The effect of PEG (either low-molecular-weight [200-400] or high-molecular-weight [>4000]) was assessed on survival after systemic inflammation induced by lipopolysaccharide or zymosan. The effects of PEG on zymosan, lipopolysaccharide, or streptolysin-induced inflammatory and bioenergetic responses of immune cells were also assessed. MEASUREMENTS AND MAIN RESULTS: Low-molecular-weight PEG reduced inflammatory cytokine expression, pyrexia, and mortality by >50% in both lipopolysaccharide and zymosan models of sepsis. Low-molecular-weight PEG reduced cytokine expression both in vivo and in vitro, and attenuated activation of human neutrophils in response to lipopolysaccharide or zymosan. By contrast, high-molecular-weight PEG conferred less significant survival effects after lipopolysaccharide and zymosan, and it did not exhibit such profound anti-inflammatory effects. Low-molecular-weight PEG attenuated lipopolysaccharide-induced activation of pro-apoptotic pathways (lysophosphatidic acid receptor and caspase-domain signaling) in the livers of endotoxemic rats. Streptolysin-induced necrosis of human neutrophils was reduced by low-molecular-weight PEG, indicating a mechanism that involves coating and/or stabilizing the cellular membrane. Low-molecular-weight PEG preserved human neutrophil responses to septic serum and bioenergetic function in macrophages and neutrophils. CONCLUSION: PEG is a commonly used, safe, nonimmunogenic molecule possessing hitherto unappreciated anti-inflammatory properties. Low-molecular-weight PEG may potentially play a role in the therapy of systemic inflammation and sepsis.
OBJECTIVE: For several chronic inflammatory disease states, therapy is enhanced by improving the pharmacokinetic properties of anti-inflammatory drugs through conjugation with polyethylene glycol. We hypothesized that part of the beneficial action of PEGylated drugs may be derived from the anti-inflammatory properties of polyethylene glycol (PEG) itself. DESIGN: Randomized, double-blinded, controlled ex vivo and in vivo laboratory studies. SETTING: University research laboratories. SUBJECTS:Human neutrophils and mononuclear cells, macrophage cell line, and adult rats and mice. INTERVENTIONS: The effect of PEG (either low-molecular-weight [200-400] or high-molecular-weight [>4000]) was assessed on survival after systemic inflammation induced by lipopolysaccharide or zymosan. The effects of PEG on zymosan, lipopolysaccharide, or streptolysin-induced inflammatory and bioenergetic responses of immune cells were also assessed. MEASUREMENTS AND MAIN RESULTS: Low-molecular-weight PEG reduced inflammatory cytokine expression, pyrexia, and mortality by >50% in both lipopolysaccharide and zymosan models of sepsis. Low-molecular-weight PEG reduced cytokine expression both in vivo and in vitro, and attenuated activation of human neutrophils in response to lipopolysaccharide or zymosan. By contrast, high-molecular-weight PEG conferred less significant survival effects after lipopolysaccharide and zymosan, and it did not exhibit such profound anti-inflammatory effects. Low-molecular-weight PEG attenuated lipopolysaccharide-induced activation of pro-apoptotic pathways (lysophosphatidic acid receptor and caspase-domain signaling) in the livers of endotoxemic rats. Streptolysin-induced necrosis of human neutrophils was reduced by low-molecular-weight PEG, indicating a mechanism that involves coating and/or stabilizing the cellular membrane. Low-molecular-weight PEG preserved human neutrophil responses to septic serum and bioenergetic function in macrophages and neutrophils. CONCLUSION:PEG is a commonly used, safe, nonimmunogenic molecule possessing hitherto unappreciated anti-inflammatory properties. Low-molecular-weight PEG may potentially play a role in the therapy of systemic inflammation and sepsis.
Authors: Ravinder Bamba; D Colton Riley; Richard B Boyer; Alonda C Pollins; R Bruce Shack; Wesley P Thayer Journal: Neural Regen Res Date: 2017-05 Impact factor: 5.135
Authors: Ana Ferrero-Andrés; Arnau Panisello-Roselló; Joan Roselló-Catafau; Emma Folch-Puy Journal: World J Gastroenterol Date: 2020-10-21 Impact factor: 5.742
Authors: João S Teodoro; Rui T Da Silva; Ivo F Machado; Arnau Panisello-Roselló; Joan Roselló-Catafau; Anabela P Rolo; Carlos M Palmeira Journal: Cells Date: 2022-02-16 Impact factor: 6.600
Authors: Gareth L Ackland; Vitaly Kazymov; Nephtali Marina; Mervyn Singer; Alexander V Gourine Journal: Crit Care Med Date: 2013-06 Impact factor: 7.598
Authors: Ana Ferrero-Andrés; Arnau Panisello-Roselló; Anna Serafín; Joan Roselló-Catafau; Emma Folch-Puy Journal: Int J Mol Sci Date: 2020-01-30 Impact factor: 5.923